Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of APP13007 for the Treatment of Inflammation and Pain After Cataract Surgery, Including a Corneal Endothelial Cell Sub-study

NCT04810962 is registered in ClinicalTrials.gov with Formosa Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04810962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04810962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of APP13007 for the Treatment of Inflammation and Pain After Cataract Surgery, Including a Corneal Endothelial Cell Sub-study
Lead sponsor
Formosa Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 16, 2021
Completion date
July 6, 2022
Enrollment
370 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

ocular inflammation and pain after cataract surgery